A review of life science current events reported by MedCity News this week:
A life science entrepreneur’s guide to making a great speech. And after talking with some of the entrepreneurs, here are my tips on public speaking to keep you from losing the room (and the opportunities in it).
Is it a drug? Is it a device? No, it’s FDA’s subjective “chemical action” guidance. The agency made an effort to provide guidance on this matter when it released the “Interpretation of the Term ‘Chemical Action’ in the Definition of Device Under Section 201(h) of the Federal Food, Drug, and Cosmetic Act” six months ago. However, industry experts gathered at a morning panel at the University of St. Thomas, Minnesota on Wednesday believe that the guidance is very subjective and not particularly helpful to companies developing new products.
How will Cleveland Clinic Innovations follow up its best-ever year? So what’s on tap for an encore in 2012? It appears Innovations will have a tough time matching last years’ impressive success, if only because it was such a strong year.
Trekkies rejoice! Qualcomm and X Prize offer $10 million for real-life tricorder. Qualcomm Foundation and the X Prize Foundation are challenging technology and medical innovators to develop a real-life mobile tricorder that can diagnose 15 diseases without any poking, prodding or invasive tests. For those unfamiliar with the tricorder, it’s a scanning device used by the Star Trek characters Bones and Spock in various applications, including detecting health problems noninvasively.
St. Jude Medical launches new MR-conditional pacemaker in India. To capitalize on growing demand from international markets, St. Jude Medical (NYSE:STJ) is launching a new MR-Conditional pacemaker in India that will allow patients implanted with such a pacemaker to undergo a full-body MRI scan safely.
[Photo from HD Wallpapers]
